Cargando…

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deprez, Valentine, Le Monnier, Laure, Sobhy-Danial, Jean-Marc, Grados, Franck, Henry-Desailly, Isabelle, Salomon-Goëb, Sarah, Rabin, Thibault, Ristic, Sanja, Fumery, Mathurin, Fardellone, Patrice, Goëb, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602842/ https://www.ncbi.nlm.nih.gov/pubmed/33081099 http://dx.doi.org/10.3390/jcm9103319

Ejemplares similares

Current characteristics of a population of psoriatic arthritis and gender disparities
por: Menis, Jimmy, et al.
Publicado: (2023)

Lumbar zygapophyseal joints injections under ultrasound guidance an alternative to fluoroscopy guidance in the management of low back pain
por: Touboul, Estelle, et al.
Publicado: (2022)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022)

Bone Loss, Osteoporosis, and Fractures in Patients with Rheumatoid Arthritis: A Review
por: Fardellone, Patrice, et al.
Publicado: (2020)

Biomarkers in Rheumatoid Arthritis
por: Goëb, Vincent, et al.
Publicado: (2014)

Bone Remodelling Markers in Rheumatoid Arthritis
por: Fardellone, Patrice, et al.
Publicado: (2014)

Th17 and CD24(hi)CD27(+) regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis
por: Salomon, Sarah, et al.
Publicado: (2017)

Diagnosis of Whipple’s disease with pseudorheumatoid nodules in a patient treated with biologics for rheumatoid polyarthritis
por: Doussiere, Marie, et al.
Publicado: (2023)

Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes
por: Goëb, Vincent, et al.
Publicado: (2009)

Huiles essentielles : Guide d´utilisation
por: Goeb, Philippe

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Is the Calcium Score Useful for Rheumatoid Arthritis Patients at Low or Intermediate Cardiovascular Risk?
por: Jesson, Claire, et al.
Publicado: (2022)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
por: McInnes, Iain B., et al.
Publicado: (2019)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings
por: Philippoteaux, Cécile, et al.
Publicado: (2022)

Dynamic Loading Assessment at the Fifth Metatarsal in Elite Athletes with a history of Jones Fracture
por: Hunt, Kenneth, et al.
Publicado: (2016)

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
por: Amrhein, Jan, et al.
Publicado: (2020)

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review
por: Álvarez-Reguera, Carmen, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
por: Wang, Ziteng, et al.
Publicado: (2022)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Trouvin, Anne-Priscille, et al.
Publicado: (2010)

Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection
por: Faquetti, Maria L., et al.
Publicado: (2022)

Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives
por: Promelle, Veronique, et al.
Publicado: (2021)

Managing complex perianal disease after anti-TNF failure: Where to go next?
por: Yzet, Clare, et al.
Publicado: (2022)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis
por: Goëb, Vincent, et al.
Publicado: (2005)

The F-Box Protein MEC-15 (FBXW9) Promotes Synaptic Transmission in GABAergic Motor Neurons in C. elegans
por: Sun, Yu, et al.
Publicado: (2013)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
por: Bergman, Martin, et al.
Publicado: (2023)

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Gait disorders in the elderly and dual task gait analysis: a new approach for identifying motor phenotypes
por: Auvinet, Bernard, et al.
Publicado: (2017)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Inflammatory Bowel Disease and the SARS-CoV-2 Pandemic: More Speed, Less Haste
por: Gower-Rousseau, Corinne, et al.
Publicado: (2021)

Tuning the size of a redox-active tetrathiafulvalene-based self-assembled ring
por: Bivaud, Sébastien, et al.
Publicado: (2015)

No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
por: Banse, Christopher, et al.
Publicado: (2013)

A Self-Assembled Electro-Active M(8)L(4) Cage Based on Tetrathiafulvalene Ligands
por: Goeb, Sébastien, et al.
Publicado: (2014)

MICA and NKG2D variants as risk factors in spondyloarthritis: a case–control study
por: Fechtenbaum, Marie, et al.
Publicado: (2018)

Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis
por: Yi, Guanqun, et al.
Publicado: (2022)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrdj34jp09c9s0ios8c8f1arbd